Abstract 112P
Background
Biliary tract cancers (BTC), including cholangiocarcinomas (CCA) are rare but aggressive cancers primarily affecting patients (pts) >70 years (median age at diagnosis : 72-78 years). However, there has been a rise in the incidence of CCA among younger individuals (<50 years). This study aimed to investigate clinical, genomic and transcriptomic characteristics and outcomes of young-onset BTC/CCA (YOC) pts.
Methods
We identified all consecutive patients with histologically confirmed CCA treated at Gustave Roussy (France) between 2015 and 2021 as part of the ACABI-PRONOBIL multicenter cohort study. Clinical data were extracted from medical records. Genomic data were obtained through in-house or Foundation Medicine® panels. Transcriptomic analyses were performed for 58 pts (13 YOC) at metastatic diagnosis.
Results
Of the 546 pts with CCA, 92 (16.8%) had YOC (median age, 42 years; range, 27-50). Median overall survival (mOS) from 1st line therapy was 22.7 months (mo) (95%CI: 18.3-27.6) for YOC patients vs 19.2 mo (95%CI: 18.0-22.0) for non-YOC patients (p=0.14). Molecular profiling was more often performed for YOC pts (68% vs 55%, p<0.05). Rates of actionable molecular alterations (IDH1/2, BRAF, FGFR2, NTRK, HER2, MSI) and targeted therapies administration did not differ between YOC and non-YOC pts. CDKN2A alterations were less frequent in YOC than in non-YOC pts (12.6% vs 25.2%, p<0.05). Differentially expressed genes between YOC and non-YOC pts with Gene Set Enrichment Analysis were mostly genes involved in immunity and WNT signaling pathways. Table: 112P
| Genomic characteristics | Age <=50 n=92 | age>50 n=454[BA1] | |||
| n | % | n | % | ||
| Molecular profile available | No | 29 | 32% | 204 | 45% |
| Yes | 63 | 68% | 250 | 55% | |
| Actionable alteration | No | 41 | 65% | 141 | 56% |
| Yes | 22 | 35% | 109 | 44% | |
| Main actionable alterations | No alteration | 11 | 17% | 43 | 17% |
| Mutation IDH1/2 | 8 | 13% | 40 | 16% | |
| Fusion FGFR 1-4 | 8 | 13% | 21 | 8% | |
| Amplification HER2 | 3 | 5% | 15 | 6% | |
| Mutation BRAF V600E | 0 | 0% | 10 | 4% | |
| EGFR | 2 | 3% | 7 | 3% | |
| Fusion NTRK | 6 | 10% | 11 | 4% | |
| Mutation KRAS G12C | 1 | 2% | 3 | 1% | |
| Other relevant alterations | KRAS | 16 | 25% | 40 | 16% |
| TP53 | 25 | 40% | 91 | 36% | |
| CDKN2A/B | 8 | 13% | 63 | 25% | |
| MMR status (n=199) | dMMR/MSI | 0 | 0% | 11 | 7% |
| pMMR/MSS | 47 | 100% | 141 | 93% | |
| Targeted therapies administration | No | 41 | 65% | 141 | 56% |
| Yes | 22 | 35% | 109 | 44% |
Conclusions
Although tending to have a more advanced disease at diagnosis, YOC patients had OS similar to that of non-YOC pts, and no more actionable molecular alterations. Our findings suggest that the biological mechanisms driving CCA in YOC patients may be different from those in older patients and warrant further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Gercor.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
669P - Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Presenter: Hyunseok Kang
Session: Poster session 17
670P - Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
Presenter: Panpan Zhang
Session: Poster session 17
671P - Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors
Presenter: Sanjay Goel
Session: Poster session 17
672P - Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Presenter: Rafal Dziadziuszko
Session: Poster session 17
673P - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Presenter: Patrick Schoeffski
Session: Poster session 17
674P - Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia
Presenter: Raymond DeMatteo
Session: Poster session 17
675P - A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Presenter: Jinming Yu
Session: Poster session 17
676P - Preclinical characterization of novel peptide binders for EphA2-targeted radiopharmaceutical therapy
Presenter: Renee Clift
Session: Poster session 17
677P - Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
Presenter: Yun Beom Sang
Session: Poster session 17
678P - ExoDS: A bioengineered exosome-based capsule for targeted delivery of chemotherapy drugs to cancer cells and cancer stem cells
Presenter: Abhishek Dutta
Session: Poster session 17